Variant: rs121913364 

    present in Gene: BRAF
    present in Chromosome: 7
    Position on Chromosome: 140753334
    Alleles of this Variant: T/C;G

rs121913364 in BRAF gene and Adenocarcinoma of lung (disorder) PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Adenocarcinoma of prostate PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Cardio-facio-cutaneous syndrome PMID 23026937 2013 Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

PMID 18042262 2008 Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.

PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 16474404 2006 Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.

PMID 16953233 2007 KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.

PMID 16439621 2006 Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

rs121913364 in BRAF gene and Chronic Lymphocytic Leukemia PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Colorectal Carcinoma PMID 24996433 2014 RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.

PMID 22855150 2012 Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

PMID 25373533 2015 Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

PMID 24455489 2014 Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.

PMID 23852704 2014 Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.

PMID 12198537 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

PMID 25006736 2014 Multitarget stool DNA testing for colorectal-cancer screening.

PMID 23263490 2013 Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.

PMID 19042984 2008 National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

PMID 17060676 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

PMID 23012255 2012 ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

PMID 23429431 2013 Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

PMID 21917714 2011 Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF.

PMID 22138009 2011 NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

rs121913364 in BRAF gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and Neoplasms PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

rs121913364 in BRAF gene and Non-Small Cell Lung Carcinoma PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

rs121913364 in BRAF gene and Noonan Syndrome PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 16953233 2007 KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 23026937 2013 Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

rs121913364 in BRAF gene and Thyroid Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913364 in BRAF gene and melanoma PMID 22972589 2013 Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 22048237 2012 Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

PMID 14679157 2003 Determinants of BRAF mutations in primary melanomas.

PMID 21639808 2011 Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 22663011 2012 Improved survival with MEK inhibition in BRAF-mutated melanoma.